Latest Healthtech Startup Funding Rounds
Companies building technology for healthcare delivery, diagnosis, clinical workflows and patient access.
- Rounds
- 752 Jan 1 – Oct 25, 2026
- Disclosed funding
- $25.9B 611 disclosed amounts
- Median round
- $16M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| I Whole-genome sequencing and bioinformatics platform for precision oncology | $31M | Series B | Healthtech, Biotech | United States | Investors | |
| A AiforiaCompany profile Aiforia builds AI software that helps pathologists analyse digital images of tissue samples. Aiforia builds AI software that helps pathologists analyse digital images of tissue samples. | ≤€20M | Venture debt facilityUndisclosed | Healthtech | Finland | Investors | |
| G GravieCompany profile Provides health benefits that help employers and employees access and pay for healthcare. Provides health benefits that help employers and employees access and pay for healthcare. | Undisclosed | Growth | Healthtech | United States | Investors | |
| S SoundHealthCompany profile Developing personalized, AI-enabled, non-invasive devices for breathing and sleep disorders. Developing personalized, AI-enabled, non-invasive devices for breathing and sleep disorders. | $12.3M | Series A | Healthtech | United States | Investors | |
| WA Woodway AssuranceCompany profile Canadian technology company behind EviData, an automated, AI-enabled platform for data privacy assurance. Canadian technology company behind EviData, an automated, AI-enabled platform for data privacy assurance. | Undisclosed | Undisclosed | Healthtech | Canada | Investors | |
 Adjuvia TherapeuticsCompany profile Adjuvia develops oral nanoparticle therapies intended to address mitochondrial dysfunction, starting with its ATI-105 program for rare diseases. Adjuvia develops oral nanoparticle therapies intended to address mitochondrial dysfunction, starting with its ATI-105 program for rare diseases. | $8M | Seed | Healthtech, Biotech | United States | Investors | |
| PB Physician-led behavioral health services and technology company | $14.2M | Growth | Healthtech | United States | Investors | |
| TB Developing nerve-targeted imaging technologies for surgery. | Undisclosed | Series A | Healthtech, Biotech | United States | Investors | |
| Q QureightCompany profile End-to-end imaging company for clinical trials with a focus on lung and heart disease. End-to-end imaging company for clinical trials with a focus on lung and heart disease. | $20M | Series B | Healthtech | United Kingdom | Investors | |
| A AurenarCompany profile Developer of a non-invasive, single-use neuromodulation platform to reduce life-threatening complications in ICU patients. Developer of a non-invasive, single-use neuromodulation platform to reduce life-threatening complications in ICU patients. | $5.7M | Seed | Healthtech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1General Catalyst
Baba, Disha (formerly Curelink), Thatch
23rounds2led - 2Y Combinator (YC)
Vitalize, Angle Health, Metriport
21rounds0led - 3Alumni Ventures
MintNeuro, Evvy, Hopscotch Primary Care
13rounds0led - 4Andreessen Horowitz (a16z)
Sharp Performance, General Medicine, Devoted Health
12rounds2led - 5Khosla Ventures
Even Healthcare, Abby Care, Rightway
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.